Jay Lalezari, CEO of CytoDyn, explains how the CCR5 receptor has emerged as a pivotal target in metastatic cancers due to its ...

Craig Ackerman, partner in the Alexander Group and lead of its medical device practice, discusses how events from the past ...

In today’s Pharmaceutical Executive Daily, WeightWatchers plans to offer Novo Nordisk’s oral Wegovy pending FDA approval, FDA ...

New regulatory initiatives in 2026 impacted DE&I, creating challenges and opportunities for the pharmaceutical industry. Companies are urged to integrate DE&I into core operations, focusing on patient ...

In today’s Pharmaceutical Executive Daily, Richard Pazdur is named director of FDA’s Center for Drug Evaluation and Research, ...

FDA Commissioner Marty Makary announced FDA’s plans for a new drug approval pathway named the Plausible Mechanism Pathway ...

Metagenomi also announced a multitude of updates, including financial results for the quarter, a strategic company evolution focusing capital on the development of its wholly owned MGX-001 hemophilia, ...

Both The U.S. Department of Health and Human Services (HHS) and the FDA announced the appointment of Richard Pazdur, M.D., as ...

Bristol Myers Squibb and Sarah Cannon Research Institute expanded their strategic collaboration, leveraging SCRI’s Accelero ...

Per the FDA's request, HHS is updating hormone therapy labels, removing misleading warnings to empower women in managing ...

AstraZeneca is the stock to beat in the United Kingdom. The global pharmaceutical company saw its stock rise to its all-time ...

In today’s Pharmaceutical Executive Daily, we report on new data showing Wegovy’s potential to reduce liver injury in patients with MASH, Eli Lilly’s latest strategic collaborations in gene therapy, ...